This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nathan Sadeghi-Nejad


Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza┬┐s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Nathan Sadeghi-Nejad
By This Author:
« Back
Page 1 of 5

A Buysider's Preview of Biotech's Biggest Conference

By Nathan Sadeghi-Nejad

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

07:00AM 01/02/13

Breaking Up With Gilead Sciences

By Nathan Sadeghi-Nejad

Gilead is a great company and stock, but expectations are high and outperformance in 2013 will be tough.

07:00AM 12/17/12

Time For Common Sense Gun Control Has Arrived

By Nathan Sadeghi-Nejad

The tragedy in Newtown should bring gun owners and opponents together.

06:30AM 12/17/12

Sarepta Is Still A Buy: Recent Concerns Much Ado About Nothing

By Nathan Sadeghi-Nejad

Eteplirsen is a blockbuster drug for DMD, a view bolstered by Friday's 62-week data.

09:00AM 12/10/12

Thoughts on Bio-Pharma Investor Sentiment Going Into 2013

By Nathan Sadeghi-Nejad

Medical innovation is increasing but ever-escalating drug prices aren't sustainable.

07:00AM 12/03/12

Nate Sadeghi's 2012 Biotech Stock Report Card

By Nathan Sadeghi-Nejad

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

07:00AM 11/26/12

Seattle Genetics: A Short Thesis That's Been Right And Wrong

By Nathan Sadeghi-Nejad

Sales of the cancer drug Adcetris have fallen short but Seattle Genetics' stock price climbs higher.

07:00AM 11/12/12

Arena Pharma Is Still A Good Short

By Nathan Sadeghi-Nejad

A marginal effective weight-loss pill sold into an overhyped market by a mediocre partner makes Arena a short.

07:00AM 11/05/12

Achillion Pharma Worthy of New Look

By Nathan Sadeghi-Nejad

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

08:16AM 10/31/12

United Therapeutics Could Lose The Battle For PAH Therapies

By Nathan Sadeghi-Nejad

An FDA decision expected this week could easily go against United Therapeutics.

07:00AM 10/22/12

« Back
Page 1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs